Navigation Links
Perrigo Reports Record Third Quarter
Date:5/7/2009

try to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                              PERRIGO COMPANY
                     CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                      (in thousands, except per share amounts)
                                     (unaudited)

                                     Third Quarter         Year-to-Date
                                     -------------         ------------
                                     2009      2008        2009       2008
                                     ----      ----        ----       ----

      Net
'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Brownsville, TX (PRWEB) October 22, 2014 On ... will present its fourth annual family health and fitness fair ... Hispanic family physical activity and good nutrition for better health ... This event, which is free and open to the public, ... Street, in Brownsville, from 9:00 am to 1:00 pm. ...
(Date:10/22/2014)... October 22, 2014 Isabel Healthcare ... Allied Health Professions (ASAHP) Conference on October 22-24 in ... will participate in a panel discussion on Technology in ... Isabel Healthcare provides a diagnostic decision support tool and ... diagnosis skills of students and clinical learners. The Isabel ...
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
... May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today ... Bay Shore, Long Island. This Center is the Company,s ... new markets that CRH has targeted for,expansion. The opening ... 2008 bringing the Company,s total number of Centers to ...
... lead unhealthy lifestyles are more likely to suffer from ... population-based study of more than 5,000 men and women ... journal BJU International. Researchers hope the results will help ... can be managed more effectively. , According to ...
... Revenue Increased 70.9% to $9.2 Million, CHENGDU, ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of ... today announced fiscal results for its third quarter ... quarter of 2008 increased 70.9% to approximately,$9.2 million ...
... to be Webcast Live at 2:00 p.m. ET Thursday, ... Inc.,(Nasdaq: CYNO ), a leading developer and manufacturer ... announced that its senior,management will present at the 2008 ... the Hilton New York., Cynosure,s presentation will be ...
... MONTVALE, N.J., May 15 Pain is a ... are an important option,for these patients. Physicians must ... the best outcomes for their patients., To ... the proper,opioid analgesic, the dual journals Current Clinical ...
... mouse model hint of new treatment strategies for the disease ... fat, the kind often found in baked and fried goods, ... The finding by University of California, Los Angeles, scientists is ... mouse model that closely mimics human cancer. , The fat ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 3Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 5Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 6Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 7Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 8Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 9Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 10Health News:Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference 2Health News:Treat Your Patients' Pain Effectively 2Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... Va., April 25, 2012 The Foundation for Managed Care ... 12th Annual National Student Pharmacist Pharmacy & Therapeutics (P&T) Competition ... is the philanthropic arm of the Academy of Managed Care ... AMCP,s 24th Annual Meeting & Expo in San Francisco. ...
... April 25, 2012  New post-hoc analyses of pivotal ... patients with Restless Legs Syndrome (RLS)/Willis Ekbom disease ... using changes in individual International RLS Study Group ... versus placebo were observed in most of the ...
Cached Medicine Technology:Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters 2Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters 3First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 2First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 3First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 4First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 5First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 6First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 7First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 8First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 9First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies 10
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
Medicine Products: